US FDA Issues Guidance Outlining Process For Requesting DSCSA Waivers
Executive Summary
Pharmaceutical manufacturers now have, at long last, guidance from FDA on the process for applying for exceptions and waivers under DSCSA. Yet they don't have much time to act as the new serialization requirements go into effect this November. Exception requests have to be submitted soon.
You may also be interested in...
Industry Groups Seek Clarity On FDA's Draft Waiver Guidance Under DSCSA
Pharmaceutical industry groups want more direction on how non-direct trading partners will be notified that a drug has been granted a waiver, exception or exemption (WEE) request under DSCSA so that good product is not deemed suspect and thrown out. There were also calls to expand the list of drugs eligible for exemption to include temperature-sensitive drugs as well as orphan drugs.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.